{{brizy_dc_image_alt imageSrc=
PARTICIPATE

A novel therapeutic giving cancer patients new hope.

We are focused on rapidly advancing our lead therapeutic candidate, misetionamide (GP-2250), for the treatment of multiple cancer types, including ovarian and pancreatic cancers.

Learn More
{{brizy_dc_image_alt imageSrc=

Adidas Ultra Boost III

$129 ... $89

GET 20% OFF

OUR SCIENCE

Disrupting cancer cell

metabolism.

Our unique and novel mechanism of action selectively disrupts the energy metabolism of cancer cells

leading to cancer cell death as well as impacting nuclear factor-κB (“NFκB”) which effects cancer cells’

ability for protein synthesis and DNA transcription thereby restricting cancer cell

growth and proliferation.

Discover Our Science

OUR PIPELINE

Focused on Addressing Unmet Needs For Patients with Cancer.

{{brizy_dc_image_alt imageSrc=

OVARIAN

CANCER

{{brizy_dc_image_alt imageSrc=

PANCREATIC

CANCER

{{brizy_dc_image_alt imageSrc=

ADDITIONAL

TARGETS

Melanoma, Squamous

Cell, Breast, Colorectal

Preclinical research with Misetionamide demonstrated significant anti-cancer activity in numerous established and primary cell lines. Misetionamide’s novel MOA and degree of preclinical activity is exciting and could be a potentially important addition to the oncologists’ armamentarium to benefit patients.

Prof. Dr. med. Chris Braumann

EvK Gelsenkirchen, University of Duisburg-Essen, Germany

It is so refreshing to work with an organization that not only shares wholeheartedly inour mission to improve survival and quality of life for patients, but has truly uniquescience that provides new hope in

the fight against cancer.

Prof. Dr. med. Chris Braumann

EvK Gelsenkirchen, University of Duisburg-Essen, Germany

It is so refreshing to work with an organization that not only shares wholeheartedly inour mission to improve survival and quality of life for patients, but has truly uniquescience that provides new hope in

the fight against cancer.

Prof. Dr. med. Chris Braumann

EvK Gelsenkirchen, University of Duisburg-Essen, Germany

It is so refreshing to work with an organization that not only shares wholeheartedly inour mission to improve survival and quality of life for patients, but has truly uniquescience that provides new hope in

the fight against cancer.

Prof. Dr. med. Chris Braumann

EvK Gelsenkirchen, University of Duisburg-Essen, Germany

Truly novel.

Truly important.

We are on a mission to improve therapeutic outcomes for cancer patients with misetionamide, a tumor-cell selective agent with a truly novel mechanism of action.

{{brizy_dc_image_alt imageSrc=

Focused on what

matters most.

In addition to demonstrating direct anti-cancer activity, misetionamide has shown pro-inflammatory cytokine suppression in preclinical studies.​

Misetionamide’s inhibition of c-MYC potentially offers the opportunity of enhancing immunotherapy as well.​

We have chosen to focus on the treatment of ovarian and pancreatic cancers as our initial indications, two conditions with a clear unmet medical need. Early clinical experience is promising.​

Participate In our ongoing pancreatic cancer Research Study
{{brizy_dc_image_alt imageSrc=

The Latest

PUBLICATION

Publication Summary – Misetionamide (GP-2250)

A summary of all publications with links to full document

POSTER

Publication Summary – Misetionamide (GP-2250)

Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors

PRESS RELEASE - 13 JUNE 2025

Publication Summary – Misetionamide (GP-2250)

A summary of all publications with links to full document

PRESS RELEASE - 14 NOVEMBER 2024

Publication Summary – Misetionamide (GP-2250)

Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors

{{brizy_dc_image_alt imageSrc=

+1.610.922.1910

Copyright © 2025 Panavance Therapeutics Inc.

Our Home

About

Resources

Participate